Kazinol B通过抑制JNK信号通路减轻缺氧/再氧诱导的肝细胞损伤。

Q3 Medicine
Yi Zhu, Junhui Li, Min Yang, Pengpeng Zhang, Cai Li, Hong Liu
{"title":"Kazinol B通过抑制JNK信号通路减轻缺氧/再氧诱导的肝细胞损伤。","authors":"Yi Zhu, Junhui Li, Min Yang, Pengpeng Zhang, Cai Li, Hong Liu","doi":"10.11817/j.issn.1672-7347.2025.240524","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Hypoxia/reoxygenation (H/R) injury is a critical pathological process during liver transplantation. Kazinol B has known anti-inflammatory, anti-apoptotic, and metabolic regulatory properties, but its protective mechanism in H/R-induced liver injury remains unclear. This study aims to investigate the protective effects and underlying mechanisms of Kazinol B in H/R-induced hepatocyte injury.</p><p><strong>Methods: </strong>An ischemia-reperfusion model was established in healthy adult male Sprague-Dawley rats, and an in vitro H/R model was created using cultured hepatocytes. Hepatocytes were treated with Kazinol B (0-100 μmol/L) to assess cytotoxicity and protective effects. Cell viability was evaluated using the cell counting kit-8 (CCK-8) and lactate dehydrogenase (LDH) release assays. Expression of apoptosis-related proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated death promoter (Bad), and cleaved caspase-3, was detected by Western blotting. Reactive oxygen species (ROS) levels were assessed via fluorescence probes, and inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were measured using enzyme-linked immunosorbent assay (ELISA). TdT-mediated nick end labeling (TUNEL) staining was performed to assess DNA damage and apoptosis.</p><p><strong>Results: </strong>Kazinol B had no significant effect on hepatocyte viability at 0-50 μmol/L, but showed cytotoxicity at 100 μmol/L (<i>P</i><0.05). At 0.1-20 μmol/L, Kazinol B significantly improved cell survival, reduced LDH release, decreased apoptosis, and attenuated DNA damage (all <i>P</i><0.001). At 10 μmol/L, Kazinol B markedly down-regulated Bad and cleaved caspase-3 (both <i>P</i><0.05), and up-regulated Bcl-2 (<i>P</i><0.01). It also dose-dependently reduced ROS levels and inflammatory cytokines TNF-α and IL-1β (all <i>P</i><0.01). Both in vitro and in vivo, Kazinol B inhibited activation of the c-Jun N-terminal kinase (JNK) pathway without affecting extracellular regulated protein kinase (ERK) signaling (<i>P</i>>0.05). TUNEL staining showed that the protective effect of Kazinol B against apoptosis was partially reversed by the JNK agonist anisomycin (<i>P</i><0.01).</p><p><strong>Conclusions: </strong>Kazinol B mitigates hepatocyte injury induced by H/R by inhibiting the JNK signaling pathway. Its protective effect is associated with suppression of oxidative stress and inflammation, indicating its potential as a hepatoprotective agent.</p>","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 2","pages":"181-189"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Kazinol B alleviates hypoxia/reoxygenation-induced hepatocyte injury by inhibiting the JNK signaling pathway.\",\"authors\":\"Yi Zhu, Junhui Li, Min Yang, Pengpeng Zhang, Cai Li, Hong Liu\",\"doi\":\"10.11817/j.issn.1672-7347.2025.240524\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Hypoxia/reoxygenation (H/R) injury is a critical pathological process during liver transplantation. Kazinol B has known anti-inflammatory, anti-apoptotic, and metabolic regulatory properties, but its protective mechanism in H/R-induced liver injury remains unclear. This study aims to investigate the protective effects and underlying mechanisms of Kazinol B in H/R-induced hepatocyte injury.</p><p><strong>Methods: </strong>An ischemia-reperfusion model was established in healthy adult male Sprague-Dawley rats, and an in vitro H/R model was created using cultured hepatocytes. Hepatocytes were treated with Kazinol B (0-100 μmol/L) to assess cytotoxicity and protective effects. Cell viability was evaluated using the cell counting kit-8 (CCK-8) and lactate dehydrogenase (LDH) release assays. Expression of apoptosis-related proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated death promoter (Bad), and cleaved caspase-3, was detected by Western blotting. Reactive oxygen species (ROS) levels were assessed via fluorescence probes, and inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were measured using enzyme-linked immunosorbent assay (ELISA). TdT-mediated nick end labeling (TUNEL) staining was performed to assess DNA damage and apoptosis.</p><p><strong>Results: </strong>Kazinol B had no significant effect on hepatocyte viability at 0-50 μmol/L, but showed cytotoxicity at 100 μmol/L (<i>P</i><0.05). At 0.1-20 μmol/L, Kazinol B significantly improved cell survival, reduced LDH release, decreased apoptosis, and attenuated DNA damage (all <i>P</i><0.001). At 10 μmol/L, Kazinol B markedly down-regulated Bad and cleaved caspase-3 (both <i>P</i><0.05), and up-regulated Bcl-2 (<i>P</i><0.01). It also dose-dependently reduced ROS levels and inflammatory cytokines TNF-α and IL-1β (all <i>P</i><0.01). Both in vitro and in vivo, Kazinol B inhibited activation of the c-Jun N-terminal kinase (JNK) pathway without affecting extracellular regulated protein kinase (ERK) signaling (<i>P</i>>0.05). TUNEL staining showed that the protective effect of Kazinol B against apoptosis was partially reversed by the JNK agonist anisomycin (<i>P</i><0.01).</p><p><strong>Conclusions: </strong>Kazinol B mitigates hepatocyte injury induced by H/R by inhibiting the JNK signaling pathway. Its protective effect is associated with suppression of oxidative stress and inflammation, indicating its potential as a hepatoprotective agent.</p>\",\"PeriodicalId\":39801,\"journal\":{\"name\":\"中南大学学报(医学版)\",\"volume\":\"50 2\",\"pages\":\"181-189\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中南大学学报(医学版)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.11817/j.issn.1672-7347.2025.240524\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中南大学学报(医学版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.11817/j.issn.1672-7347.2025.240524","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:缺氧/再氧化(H/R)损伤是肝移植过程中一个重要的病理过程。Kazinol B具有已知的抗炎、抗凋亡和代谢调节特性,但其在H/ r诱导的肝损伤中的保护机制尚不清楚。本研究旨在探讨Kazinol B对H/ r诱导的肝细胞损伤的保护作用及其机制。方法:建立健康成年雄性Sprague-Dawley大鼠缺血再灌注模型,并利用培养的肝细胞建立体外H/R模型。用0 ~ 100 μmol/L Kazinol B处理肝细胞,观察其细胞毒性和保护作用。采用细胞计数试剂盒-8 (CCK-8)和乳酸脱氢酶(LDH)释放法评估细胞活力。Western blotting检测凋亡相关蛋白、b细胞淋巴瘤2 (Bcl-2)、Bcl-2相关死亡启动子(Bad)和cleaved caspase-3的表达。采用荧光探针检测活性氧(ROS)水平,采用酶联免疫吸附法(ELISA)检测炎症因子肿瘤坏死因子-α (TNF-α)和白细胞介素-1β (IL-1β)水平。tdt介导的缺口末端标记(TUNEL)染色评估DNA损伤和细胞凋亡。结果:Kazinol B在0 ~ 50 μmol/L浓度下对肝细胞活力无显著影响,但在100 μmol/L浓度下具有细胞毒性(PPPPPP>0.05)。TUNEL染色显示,Kazinol B对凋亡的保护作用被JNK激动剂大霉素部分逆转(p结论:Kazinol B通过抑制JNK信号通路减轻H/R诱导的肝细胞损伤。其保护作用与抑制氧化应激和炎症有关,表明其作为肝保护剂的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Kazinol B alleviates hypoxia/reoxygenation-induced hepatocyte injury by inhibiting the JNK signaling pathway.

Objectives: Hypoxia/reoxygenation (H/R) injury is a critical pathological process during liver transplantation. Kazinol B has known anti-inflammatory, anti-apoptotic, and metabolic regulatory properties, but its protective mechanism in H/R-induced liver injury remains unclear. This study aims to investigate the protective effects and underlying mechanisms of Kazinol B in H/R-induced hepatocyte injury.

Methods: An ischemia-reperfusion model was established in healthy adult male Sprague-Dawley rats, and an in vitro H/R model was created using cultured hepatocytes. Hepatocytes were treated with Kazinol B (0-100 μmol/L) to assess cytotoxicity and protective effects. Cell viability was evaluated using the cell counting kit-8 (CCK-8) and lactate dehydrogenase (LDH) release assays. Expression of apoptosis-related proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated death promoter (Bad), and cleaved caspase-3, was detected by Western blotting. Reactive oxygen species (ROS) levels were assessed via fluorescence probes, and inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were measured using enzyme-linked immunosorbent assay (ELISA). TdT-mediated nick end labeling (TUNEL) staining was performed to assess DNA damage and apoptosis.

Results: Kazinol B had no significant effect on hepatocyte viability at 0-50 μmol/L, but showed cytotoxicity at 100 μmol/L (P<0.05). At 0.1-20 μmol/L, Kazinol B significantly improved cell survival, reduced LDH release, decreased apoptosis, and attenuated DNA damage (all P<0.001). At 10 μmol/L, Kazinol B markedly down-regulated Bad and cleaved caspase-3 (both P<0.05), and up-regulated Bcl-2 (P<0.01). It also dose-dependently reduced ROS levels and inflammatory cytokines TNF-α and IL-1β (all P<0.01). Both in vitro and in vivo, Kazinol B inhibited activation of the c-Jun N-terminal kinase (JNK) pathway without affecting extracellular regulated protein kinase (ERK) signaling (P>0.05). TUNEL staining showed that the protective effect of Kazinol B against apoptosis was partially reversed by the JNK agonist anisomycin (P<0.01).

Conclusions: Kazinol B mitigates hepatocyte injury induced by H/R by inhibiting the JNK signaling pathway. Its protective effect is associated with suppression of oxidative stress and inflammation, indicating its potential as a hepatoprotective agent.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中南大学学报(医学版)
中南大学学报(医学版) Medicine-Medicine (all)
CiteScore
1.00
自引率
0.00%
发文量
8237
期刊介绍: Journal of Central South University (Medical Sciences), founded in 1958, is a comprehensive academic journal of medicine and health sponsored by the Ministry of Education and Central South University. The journal has been included in many important databases and authoritative abstract journals at home and abroad, such as the American Medline, Pubmed and its Index Medicus (IM), the Netherlands Medical Abstracts (EM), the American Chemical Abstracts (CA), the WHO Western Pacific Region Medical Index (WPRIM), and the Chinese Science Citation Database (Core Database) (CSCD); it is a statistical source journal of Chinese scientific and technological papers, a Chinese core journal, and a "double-effect" journal of the Chinese Journal Matrix; it is the "2nd, 3rd, and 4th China University Excellent Science and Technology Journal", "2008 China Excellent Science and Technology Journal", "RCCSE China Authoritative Academic Journal (A+)" and Hunan Province's "Top Ten Science and Technology Journals". The purpose of the journal is to reflect the new achievements, new technologies, and new experiences in medical research, medical treatment, and teaching, report new medical trends at home and abroad, promote academic exchanges, improve academic standards, and promote scientific and technological progress.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信